Clinical Trials
12 trialsNCT07205536 2025-12-11
ANC-IIT-004
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT03233776 2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2 Completed
NCT04099901 2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2 Completed
NCT06143735 2023-11-22
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04477616 2023-02-23
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT02685111 2020-07-31
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Asan Medical Center
Phase 2 Terminated
NCT02544685 2019-01-17
FENSY
S&D Pharma SK s.r.o.
Phase 2 Unknown
NCT02005458 2018-07-17
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 2 Completed
NCT03449693 2018-03-05
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
Universidad Nacional Autonoma de Mexico
Phase 2 Unknown
NCT02732327 2017-07-21
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
Forest Laboratories
Phase 2 Terminated
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02119715 2014-04-22
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed